Results 151 to 160 of about 4,422 (206)

Effectiveness of oral dydrogesterone compared to placebo in reducing the risk of preterm birth: a systematic review and meta-analysis. [PDF]

BMC Pregnancy Childbirth
Hedawy S, Aldalahmeh S, Labeeb EE, Khattab AA, Khalid E, Hassan A, Menshawy A.   +6 more
europepmc   +1 more source

The use of 17-alpha-hydroxyprogesterone caproate to maintain pregnancy.

Current therapeutic research, clinical and experimental, 1998
K H, MEYERHOFF, W H, BROWN, L A, CIOFFI
openaire   +1 more source

Relación entre 17-hidroxiprogesterona sérica con el tamiz neonatal en el diagnostico de hiperplasia suprarrenal congénita en pacientes pediátricos del hospital materno infantil ISSEMYM del 01 de enero de 2010 al 31 de diciembre de 2012 [PDF]

, 2014
Ayala Estrada, Arturo, Loza Santiaguillo, Paloma del Rocio   +1 more
core  

Significance of a Three-Missense Pathogenic Variant in the Substrate-Binding Lesion in a Subject With 21-Hydroxylase Deficiency: A Case Report. [PDF]

Cureus
Harada A, Anno T, Isobe H, Kaku K, Kaneto H.   +4 more
europepmc   +1 more source

Apparent Clitoromegaly in a Newborn: A Case of Congenital Adrenal Hyperplasia. [PDF]

Cureus
Svanadze M, Gagua T, Svanadze T, Barnovi A, Morchadze M.   +4 more
europepmc   +1 more source

Strategies to inhibit steroid cytochrome P450 enzymes to benefit human health: development of steroid ligands for P450s 17A1, 19A1, and 8B1 to treat cancer and obesity. [PDF]

RSC Med Chem
Ho TM, Yoshimoto FK.
europepmc   +1 more source

High-Dose Hormone Replacement Therapy Improved Embryo Transfer Outcomes in a Woman With 21-Hydroxylase Deficiency Who Had Persistently High Serum Progesterone Levels: A Case Report and Literature Review. [PDF]

Clin Case Rep
Mizusawa Y, Shibahara H, Shiotani M.
europepmc   +1 more source

[Participation of 17 alpha-hydroxyprogesterone in the mechanism of ovulation].

Gaceta medica de Mexico, 1973
openaire   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Prevention of Recurrent Preterm Delivery by 17 Alpha-Hydroxyprogesterone Caproate

New England Journal of Medicine, 2003
Women who have had a spontaneous preterm delivery are at greatly increased risk for preterm delivery in subsequent pregnancies. The results of several small trials have suggested that 17 alpha-hydroxyprogesterone caproate (17P) may reduce the risk of preterm delivery.We conducted a double-blind, placebo-controlled trial involving pregnant women with a ...
Paul J, Meis, Mark, Klebanoff, Elizabeth, Thom, Mitchell P, Dombrowski, Baha, Sibai, Atef H, Moawad, Catherine Y, Spong, John C, Hauth, Menachem, Miodovnik, Michael W, Varner, Kenneth J, Leveno, Steve N, Caritis, Jay D, Iams, Ronald J, Wapner, Deborah, Conway, Mary J, O'Sullivan, Marshall, Carpenter, Brian, Mercer, Susan M, Ramin, John M, Thorp, Alan M, Peaceman, Steven, Gabbe   +21 more
  +8 more sources

17 Alpha-hydroxyprogesterone caproate use in a rural state

The Journal of Maternal-Fetal & Neonatal Medicine, 2021
17 alpha-hydroxyprogesterone caproate (17OHP) is used to reduce the recurrent risk of preterm delivery in women with a history of preterm delivery. Meis et al. conducted a double-blind placebo controlled trial to evaluate the effectiveness of 17OHP and observed a significant reduction in the risk of recurrent preterm delivery.
Taylor Ghahremani, Amy Phillips, Everett F. Magann, Hannah McCoy, Julie Whittington, Songthip Ounpraseuth, Hari Eswaran   +6 more
openaire   +2 more sources